AstraZeneca CEO Highlights AI's Role in Accelerating Drug Development
L'essentiel
AstraZeneca CEO Pascal Soriot discusses how AI enhances productivity in drug discovery and development, enabling smarter design, side effect reduction, and improved trial success prediction.
Résumé généré par IA
Pourquoi c'est important
AstraZeneca leverages AI for faster, smarter drug development amid investor scrutiny of AI investments.
AstraZeneca CEO Pascal Soriot highlighted the value of AI in accelerating drug development, citing productivity gains and smarter decision-making. Speaking on CNBC, Soriot noted AI's role in identifying new targets, optimizing drug design, and predicting trial success probabilities through partnerships like Tempus AI. This could significantly reduce the $300-$500 million spent on trials by increasing success odds. Investors have been questioning the ROI of AI investments, but AstraZeneca sees practical applications across its pipeline.
Soriot emphasized AI helps in removing potential side effects early and makes the development process faster and more intelligent. The company uses AI models to analyze clinical and laboratory data for better decision-making on which drugs to advance.
À surveiller
Perspective IA — des possibilités, pas des certitudes
Increased adoption of AI in pharmaceutical R&D across the industry
Probable · En quelques années
Questions ouvertes
- Specific timeline for AI-driven projects
- Detailed cost savings projections
